INVO Bioscience (INVO) Misses Q3 EPS by 4c

INVO Bioscience (NASDAQ: INVO) reported Q3 EPS of ($0.24), $0.04 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $218.9 thousand versus the consensus estimate of $330 thousand.

For earnings history and earnings-related data on INVO Bioscience (INVO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c